New Regime for Meningococcal B Vaccine: Guideline

Advisory Committee on Immunization Practices,Centers for Disease Control and Prevention, Morbidity and Mortality Weekly Report (MMWR), US has recently updated the guideline for Use of MenB-FHbp Serogroup B Meningococcal Vaccine , 2016 .

Following are the major Updated Recommendations :

These recommendations are regarding use of the 2- and 3-dose schedules of MenB-FHbp vaccine (Trumenba) and replace previous ACIP recommendations for use of MenB-FHbp vaccine published in 2015 (3,4). Recommendations regarding use of MenB-4C (Bexsero) are unchanged (3,4).

• Persons aged ≥10 years at increased risk for serogroup B meningococcal disease (Category A recommendation). For persons at increased risk for meningococcal disease and for use during serogroup B meningococcal disease outbreaks, 3 doses of MenB-FHbp should be administered at 0, 1–2, and 6 months to provide earlier protection and maximize short-term immunogenicity. However, if the second dose of MenB-FHbp is administered at an interval of ≥6 months, a third dose does not need to be administered.


• Adolescents and young adults aged 16–23 years (Category B recommendation). When given to healthy adolescents who are not at increased risk for meningococcal disease, 2 doses of MenB-FHbp should be administered at 0 and 6 months. If the second dose of MenB-FHbp is administered earlier than 6 months after the first dose, a third dose should be administered at least 4 months after the second dose.


• Recommendations for use of MenB-4C vaccine are unchanged.


• The two MenB vaccines are not interchangeable, and the same product must be given for all doses in a series.


• Either MenB vaccine may be given concomitantly with other vaccines appropriate for this age, but preferably at a different anatomic site.


• Defer vaccination in women known to be pregnant or lactating unless the woman is at increased risk for serogroup B meningococcal disease, and if her healthcare provider determines that the benefits of vaccination outweigh the potential risks.

Read the full guideline click on the link : https://www.cdc.gov/mmwr/volumes/66/wr/mm6619a6.htm